Dr. Christian Braun´s research work is focused on mechanisms of tumorigenesis and therapeutic resistance. He is employing genetic screening methods via shRNA and CRISPR/Cas9 systems in malignancies such as lymphoma and malignant glioma. In his most recent work in „Cancer Cell“ he showed that glioblastoma is selectively sensitive to the inhibition of PRMT5 and identified a predictive biomarker for this sensitivity. Moreover, PRMT5 inhibition was shown to primarily disrupt the removal of detained introns resulting in the reduction of functional transcripts of proliferation-associated genes.
Christian Braun currently is a group leader at Ludwig-Maximilians-University (LMU) Munich at the „Haunersches Kinderspital“ pediatric department. He received his training as a medical doctor at the University of Göttingen and started his career as a clinician scientist at the Hannover Medical School (MHH) and subsequently at Ludwig-Maximilians-University (LMU) Munich in the field of gene therapy. As a postdoc he joined the Hemann Lab at the D. Koch Institute for Integrative Cancer Research at Massachusetts Institute for Technology (MIT). Since 2017 he is an independent group leader and has been awarded a „Max-Eder-Nachwuchsgruppe“ recently.
To arrange an individual discussion with Christian Braun, please contact email@example.com.
Speaker: Dr. med Christian Braun
Venue: CECAD, Building 69, Lecture hall ground floor, Josef-Stelzmann-Str. 26
Time: 2 pm